One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. | One day after CSL revealed that it had suddenly replaced its CEO, the company ...
Formerly the Commonwealth Serum Laboratories, CSL grew under McNamee into a world leader in blood fractionation, where plasma ...
For decades, CSL was the golden child of the ASX, the great Australian success story: a privatised government entity turned global biotech titan.
With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...
From a student in Iloilo to an internationally recognized authority in vaccinology, Dr. Melvin Sanicas, is an expert who not ...
When does the exercise of patent rights become an antitrust violation? The apex court is now poised to answer a question that remains at the intersection of “innovation in a healthy ...
Tuesday’s sacking unfolded as a corporate coup, with the board signing off on the exit and McNamee making the captains call of installing his former trusted deputy Gordon Naylor as interim CEO. Naylor ...
Marcus Today’s Henry Jennings is unimpressed by CSL’s results - and even less so by its handling of the CEO change.
Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...
Americans pay about three times what other wealthy nations do for branded prescription drugs. For years, policymakers have tried to fix this by cutting U.S. drug prices directly. President Trump has ...
SpyGlass Pharma, Inc. (SGP) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information, although the final amount may differ. The biopharma is a ...
Pete Pharma, a leader in pharmaceutical innovation and pharmaceutical IP development, is proud to announce a strategic partnership with Curexa, a nationally recognized 503A pharmacy serving a growing ...